CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm
PR Newswire —
SAN FRANCISCO, Feb. 2, 2026 /PRNewswire/ -- The latest adverse development for Corcept Therapeutics (NASDAQ: CORT) concerning its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant – came on January 30, 2026 when Reuters reported that...